GSK (NYSE:GSK) Rating Increased to Buy at Wall Street Zen

GSK (NYSE:GSK) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other brokerages have also recently issued reports on GSK. Weiss Ratings cut shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $53.00.

GSK Stock Performance

Shares of GSK opened at $52.49 on Friday. The business has a fifty day moving average of $51.98 and a 200 day moving average of $52.93. The firm has a market capitalization of $106.31 billion, a P/E ratio of 13.64, a PEG ratio of 2.68 and a beta of 0.36. GSK has a one year low of $35.45 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52.

Institutional Trading of GSK

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GSK. Fisher Asset Management LLC lifted its position in GSK by 3.0% during the fourth quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock valued at $1,627,931,000 after purchasing an additional 968,370 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of GSK by 2,032.8% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock valued at $41,896,000 after acquiring an additional 814,275 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in GSK by 1.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock valued at $15,444,000 after purchasing an additional 4,855 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in shares of GSK in the fourth quarter worth about $6,385,000. Finally, Align Financial LLC acquired a new position in shares of GSK during the 4th quarter worth approximately $5,628,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.